Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-137589

Published: 2020

Journal Articles

Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults

Joseph Maakaron, MD, Karen Chen, MS, Mei-Jie Zhang, PhD, Christopher S. Hourigan, MDDPhil, Mark Litzow, MD, Wael Saber, MD MS, Partow Kebriaei, MD, Daniel J. Weisdorf, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141096

Published: 2020

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Hemant S. Murthy, MD, Kwang Woo Ahn, PhD, Noel Estrada-Merly, MS, Lohith Gowda, MD, Bhagirathbhai Dholaria, MBBS, Susan Bal, MDMBBS, Hassan B. Alkhateeb, MD, Deepa Jagadeesh, MDMPH, Betul Oran, MDMS, Ryotaro Nakamura, MD, Bart L. Scott, MD, Craig S. Sauter, MD, Francine M. Foss, MD, Mohamed A kharfan-Dabaja, MDMBA, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134793

Published: 2020

Journal Articles

Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study

Gregory A. Abel, MD MPH, Donnie Hebert, PhD, Cecilia Lee, DrPH, RN, James M. Foran, MD, Steven D. Gore, MD, Wael Saber, MD MS, Dana Elise Rollison, PhD, Eric Padron, MD, Steffanie H. Wilson, PhD, Jason Thompson, MS, MBA, Myron Waclawiw, PhD, Nancy L. DiFronzo, PhD, Mikkael A. Sekeres

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-136992

Published: 2020

Journal Articles

Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis

Guru Subramanian Guru Murthy, MD, Soyoung Kim, Zhen-Huan Hu, MPH, Noel Estrada-Merly, MS, Ryotaro Nakamura, MD, Betul Oran, MDMS, Bart L. Scott, MD, Ronald Sobecks, MD, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-140647

Published: 2020

Journal Articles

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136828

Published: 2020

Journal Articles

Chromosomal Aberrations in Pre-HCT Blood Samples and Outcomes after Transplantation in Patients with Myelofibrosis

Youjin Wang, PhD, Derek W Brown, PhD, Weiyin Zhou, MS, Tao Wang, PhD, Meredith Yeager, PhD, Andrew St. Martin, MS, Stephen R. Spellman, MS, Stephanie J. Lee, MDMPH, Stephen J. Chanock, MD, Wael Saber, MD MS, Mitchell Machiela, PhD, Shahinaz Gadalla, MD PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-142418

Published: 2020

Journal Articles

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140317

Published: 2020

Journal Articles

Comparison of Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide to Matched-Sibling, Matched-Unrelated, Mismatched-Unrelated, and Umbilical Cord Blood Donor Transplantation in Adults with Acute Lymphoblastic Leukemia: A CIBMTR Study

Matthew J. Wieduwilt, MD PhD, Leland Metheny, III, MD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Noel Estrada-Merly, MS, Marcos de Lima, MD, Mark Litzow, MD, Partow Kebriaei, MD, Chris S. Hourigan, MDPhD, Daniel J. Weisdorf, MD, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-137186

Published: 2020

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia

Leland Metheny, III, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD, Marcos de Lima, MD, Natalie Scott Callander, MD, Mark Litzow, MD, Partow Kebriaei, MD, Aric C. Hall, MD, Brenda M Sandmaier, MD, Mei-Jie Zhang, Hai-Lin Wang, MPH, Khalid Bo-Subait

Blood (2019) 134 (Supplement_1): 2036.

https://doi.org/10.1182/blood-2019-125946

Published: 2019

Journal Articles

Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Immune (1801)

Shernan Holtan, MD, Ami S. Bhatt, MD PhD, Raphael Fraser, PhD, Miguel-Angel Perales, MD, Leslie Kean, MD PhD, Wael Saber, MD MS, Mehdi Hamadani, MD, Brent R. Logan, Javier Bolaños-Meade, MD

Blood (2019) 134 (Supplement_1): 2005.

https://doi.org/10.1182/blood-2019-122782

Published: 2019

Journal Articles

Pediatric Intensive Care Resource Utilization Following Hematopoietic Cell Transplantation in Children with Acute Leukemia

Cameron Baldes, MD, Martha Wetzel, Courtney McCracken, PhD, Wael Saber, MD MS, Staci D. Arnold, MD MBA, MPH

Blood (2019) 134 (Supplement_1): 3428.

https://doi.org/10.1182/blood-2019-131082

Published: 2019

Journal Articles

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Betul Oran, MDMS, Kwang Woo Ahn, PhD, Caitrin Fretham, Mithun Vinod Shah, MD PhD, Ryotaro Nakamura, MD, Bart L. Scott, MD, Ronald Sobecks, MD, Uday Popat, MD, Wael Saber, MD MS

Blood (2019) 134 (Supplement_1): 253.

https://doi.org/10.1182/blood-2019-121970

Published: 2019

Journal Articles

Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR

Matthew J. Wieduwilt, MD PhD, Wendy Stock, MD, Anjali S. Advani, MD, Selina M. Luger, MD FRCPC, Richard A. Larson, MD, Martin S. Tallman, MD, Frederick R. Appelbaum, MD, Mei-Jie Zhang, Khalid Bo-Subait, Brenda M. Sandmaier, MD, Marcos de Lima, MD, Partow Kebriaei, MD, Mark Litzow, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD

Blood (2019) 134 (Supplement_1): 261.

https://doi.org/10.1182/blood-2019-128560

Published: 2019

Journal Articles

Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome

Wei Wang, Paul Auer, PhD, Stephen R. Spellman, MS, Karen-Sue B. Carlson, MD PhD, Aziz Nazha, MD, Martin Maiers, MS, Yung-Tsi Bolon, Wael Saber, MD MS

Blood (2019) 134 (Supplement_1): 4557.

https://doi.org/10.1182/blood-2019-127124

Published: 2019

Journal Articles

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Mary-Elizabeth M. Percival, MD, Hai-Lin Wang, MPH, Mei-Jie Zhang, PhD, Elihu H. Estey, MD, Mark Litzow, MD, Partow Kebriaei, MD, Marcos de Lima, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD, Brenda M Sandmaier, MD

Blood (2019) 134 (Supplement_1): 4585.

https://doi.org/10.1182/blood-2019-123510

Published: 2019

Journal Articles

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index

Nelli Bejanyan, MD, Mei-Jie Zhang, PhD, Khalid Bo-Subait, Hai-Lin Wang, MPH, Erica D. Warlick, MD, Claudio G Brunstein, MD PhD, Brenda M Sandmaier, MD, Mark Litzow, MD, Partow Kebriaei, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD

Blood (2019) 134 (Supplement_1): 4603.

https://doi.org/10.1182/blood-2019-123513

Published: 2019

Journal Articles

Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study

Blood (2019) 134 (Supplement_1): 4271.

https://doi.org/10.1182/blood-2019-126978

Published: 2019

Journal Articles

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Blood (2019) 134 (Supplement_1): 3323.

https://doi.org/10.1182/blood-2019-125865

Published: 2019

Journal Articles

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee

Aziz Nazha, Zhen-Huan Hu, MPH, Tao Wang, PhD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, R. Coleman Lindsley, MD, PhD, Ronald Sobecks, MD, Uday Popat, MD, Bart L Scott, MD, Wael Saber, MD MS

Blood (2018) 132 (Supplement 1): 206.

https://doi.org/10.1182/blood-2018-99-118677

Published: 2018

NARROW

Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study

Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Chromosomal Aberrations in Pre-HCT Blood Samples and Outcomes after Transplantation in Patients with Myelofibrosis

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Comparison of Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide to Matched-Sibling, Matched-Unrelated, Mismatched-Unrelated, and Umbilical Cord Blood Donor Transplantation in Adults with Acute Lymphoblastic Leukemia: A CIBMTR Study

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia

Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Immune (1801)

Pediatric Intensive Care Resource Utilization Following Hematopoietic Cell Transplantation in Children with Acute Leukemia

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index

Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only